Abstract. Current in vitro culture systems allow the generation of human dendritic progenitor cells (CFU-DCs). The aim of this study was to assess the effect of Flt3 ligand (FL) on the proliferation of human peripheral blood-derived myeloid CFU-DCs and their differentiation into more committed precursor cells (pDCs) using in vitro culture systems. Immunomagnetically separated CD34 + cells were cultured in serum-free, as well as in serum-containing, liquid suspension cultures to investigate the expansion and/or proliferation/ differentiation of CFU-DCs, pDCs, and more mature dendritic cells (DCs). FACS-sorted CD34 + Flt3 +/-cells were cultured in methylcellulose to assay hematopoietic progenitors, including CFU-DCs. In the clonal cell culture supplemented with granulocyte/macrophage (GM) colony-stimulating factor (CSF), interleukin-4, and tumor necrosis factor α, the frequency of CFU-DCs was significantly higher in the CD34 + Flt3 + fraction than in the CD34 + Flt3 -population, thus suggesting functional Flt3 expression on CFU-DCs. Serum-free suspension culture of CD34 + cells revealed the potent effect of FL on the expansion of CFU-DCs in synergy with GM-CSF and thrombopoietin (TPO). In addition, FL strongly induced the maturation of CFU-DCs into functional CD1a + pDCs in serum-containing liquid suspension culture. Moreover, these FL-generated pDCs showed remarkable potential to differentiate into mature DCs with surface CD83/CD86 expression, which induced a distinct allogeneic T-cell response. These results clearly demonstrate that FL supports not only the proliferation of early hematopoietic progenitor cells, but also the maturation process of committed precursor cells along with the DC-lineage differentiation. Therefore, it is possible to develop a more efficient DC-based cancer immunotherapy using this specific cytokine combination, GM-CSF+TPO+FL in vitro in the near future.
Introduction
Hematopoietic stem cells (HSCs) are known to have a robust capacity of multilineage differentiation, which is mainly regulated by the extrinsic environment, including cytokines or adhesion molecules expressed on neighboring cells (1, 2) . However, targeted deletion or overexpression of lineagespecific transcription factors leads to recovery of the differentiation potential into alternative lineages. For instance, pre-B cells in Pax-5-null mice can differentiate into mature T lymphoid and myeloid cells despite their defective potential for B lymphoid maturation (3) . In addition, with the enforced expression of a myeloid-restricted cytokine receptor (R), granulocyte/macrophage colony-stimulating factor-R (GM-CSF-R) on hematopoietic progenitors (HPCs) results in a biased generation of myeloid cells (4) . Lineage restriction in HSC/HPC differentiation may thus be controlled not only stochastically by intrinsic factors, but also instructively by expression levels of transcription factors or cytokine receptors.
Dendritic cells (DCs) are known as one of the most important players in the regulation of innate and adaptive immunity (5) (6) (7) (8) . They are recruited from the HSC pool like cells in other hematopoietic lineages (9) (10) (11) (12) (13) . In mice, several DC compartments have been identified according to their immunophenotypes. It has also been reported that DCs are produced only from HPCs which express Flt3 on their surfaces (14, 15) .
While Flt3 is a receptor tyrosine kinase showing some structural homology to c-kit and c-fms (16) (17, 18) . In human hematopoiesis, FL acts on the proliferation and differentiation of myeloid as well as erythroid stem/ progenitor cells in vitro in synergy with other early-acting cytokines, such as stem cell factor (SCF, c-kit ligand) and thrombopoietin (TPO) (19) (20) (21) (22) (23) -5 mol/l 2-mercaptoethanol (Sigma), and 5 CSFs (20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml GM-CSF, 20 ng/ml G-CSF, and 2 U/ml Epo). Dishes were incubated at 37˚C in a fully humidified atmosphere flushed with a combination of 5% CO 2 , 5% O 2 , and 90% N 2 . On days 12-14 of incubation, colonies were scored according to their typical morphological features using an inverted microscope, as reported (26-30). Colony types identified in situ were granulocyte/macrophage (CFU-GM), erythroid (BFU-E), and erythrocyte-containing mixed (CFU-Mix) colonies.
To examine dendritic colony (CFU-DC) formation, 500 sorted CD34 + Flt3 + or -cells or cells recovered from serumcontaining liquid cultures described below were cultured in the presence of 20 ng/ml GM-CSF, 100 U/ml IL-4, and 100 U/ml TNFα. On days 12-14 of incubation, DC colonies were scored, as described previously (31).
Liquid suspension culture. A total of 5x10 3 immunomagnetically isolated CD34 + or Lin -cells were cultured in 35-mm Lux suspension dishes containing 1 ml of StemPro-34 medium (Invitrogen) supplemented with the designated combination of CSFs, which included 20 ng/ml GM-CSF, 100 ng/ml TPO, 20 ng/ml SCF, and 20 ng/ml FL. Dishes were incubated at 37˚C in a fully humidified chamber flushed with a combination of 5% CO 2 , 5% O 2 , and 90% N 2 . On day 7, half of the culture medium was exchanged with freshly prepared medium. After 14 days of incubation, the number of viable cells in each dish was counted and replaced into clonal cell cultures.
In addition, CD34 + or Lin -cells were incubated in RPMI 1640 (Invitrogen) supplemented with 10% FCS and the designated factors. After 14 days of incubation, these cells were transferred into DC maturation culture medium containing 10% FCS/RPMI supplemented with GM-CSF, IL-4, and TNFα. On day 7, 14, and 21 of incubation, a portion of cultured cells was processed for flow cytometry, as described below.
Flow cytometry. Immunomagnetically isolated cells or cells harvested from suspension cultures were stained with FITCconjugated mAbs against human CD11c (eBioscience, San Diego, CA, USA), CD14 (BD), CD54 (Beckman Coulter, Fullerton, CA, USA), CD80 and CD86 (both from Caltag Laboratories, Burlingame, CA, USA), PE-conjugated antihuman CD1a (Coulter), CD83 (Caltag), and HLA-DR (BD) mAbs. Dead cells were gated out by simultaneous staining with 7-AAD (Coulter). Data acquisition and analysis were performed using CELLQuest software on a FACSCalibur (BD).
Mixed lymphocyte reaction (MLR).
The antigen-presenting capacities of DCs were assessed by MLR, as previously described (25), with some modifications. In brief, allogeneic T-cells were isolated as responders using nylon fiber columns (Wako, Osaka, Japan). A total of 1x10 5 cells were incubated in 96-well microtiter plates (Nunc) with the designated numbers of γ-irradiated (250 cGy) DCs generated from CD34 + cells in the above-mentioned serial liquid suspension culture for 21 days. Statistical analysis. The significance of differences was determined by the paired t-test.
Results

Functional expression of Flt3 on human DC progenitors.
We first investigated the Flt3 receptor expression on PB-derived CD34 + cells. As shown in Fig. 1a and b cell fraction (P<0.01). In addition, CD34 + Flt3 + cells generated a significantly (P<0.01) higher number of CFU-GM-derived colonies, while most colonies in cultures of CD34 + Flt3 -cells were derived from BFU-E or CFU-Mix (P<0.01). These results indicated the possibility that Flt3 is expressed as a functional molecule on CFU-DC as well as CFU-GM.
Ex vivo expansion of DC progenitors by FL.
It has been well documented that GM-CSF has the most potent effect on the DC-lineage differentiation of hematopoietic progenitors (HPCs) (11), while TPO, SCF, and FL have been shown to synergistically support the efficient expansion of early hematopoietic stem/progenitor cells in vitro (21, 24, 25) . A combination of these early-acting CSFs also strongly enhances the proliferation of CD1a + precursor DCs (pDCs) (24,25). On the other hand, c-kit and Flt3, which are activated with their respective ligands, SCF and FL, have been shown to have similar but specific tyrosine kinase activities (32). We therefore aimed to evaluate and compare the effect of FL and SCF on the proliferation of DC progenitors.
Representative data from three independent serum-free suspension cultures of CD34 + cells are shown in Fig. 2 . Although the total cell number at day 14 significantly (P<0.05) increased in the cultures containing GM-CSF+TPO+SCF (GTS) or GM-CSF+TPO+FL (GTF), in comparison to GM-CSF+TPO (GT), no significant difference was observed between GTS and GTF. The proliferation of DC progenitors (CFU-DCs) was more strongly supported by GTF than by GTS (P<0.05), while a combination of four cytokines (GTSF) did not enhance CFU-DC proliferation more profoundly. These results suggest that, in comparison to SCF, FL acts more specifically and potently on the proliferation of myeloid DC progenitors expressing its receptor Flt3, as well as on other lineage-committed progenitors.
Differentiation of CD34 + cells to DC precursors (pDCs) by FL.
We assessed the serial effects of FL on the DC-lineage differentiation of CD34 + HPCs. Purified CD34 + cells were cultured in serum-containing media supplemented with GTS, GTF or GTSF. After 14 days of culture with GTS, ~10% of cells weakly expressed both CD11c and CD1a antigens (Fig. 3b) , which are specific for pDCs. Interestingly, >50% of cells expressed these antigens after the same period of culture with GTF, whose fluorescence intensities were significantly higher than those with GTS (Fig. 3e) . On the other hand, a combination of GTSF did not increase these DC-markers' expression as compared to GTF (Fig. 3h) . Cells harvested from cultures supplemented with GTS, GTF and GTSF were further incubated with G4TN for another 7 days. As shown in Fig. 3c , f and i, the expression levels of CD11c and CD1a in these cells on day 21 were comparable despite the initial cytokine combination. These results indicate that FL can accelerate the differentiation of CD34 + HPCs to pDCs. As with CD11c expression, a combination of GTF induced the differentiation of CD34 + cells to CD14 + CD1a + pDCs more rapidly than GTS or GTSF (Fig. 4b , e and h). As clearly seen in Fig. 4 pDCs, regardless of the initial cytokine combination used in the first step serum-containing culture. As well-documented in previous literature, neither CD11c, CD14 or CD1a, however, directly show the immunological function of DCs or pDCs. Therefore, it seems most important to clarify whether FL could contribute to the effective generation of functional and beneficial pDCs or not.
We compared the expression profiles of active antigenpresenting cell (APC) markers, CD83 and CD86, on culturegenerated DCs induced in the maturation cultures containing G4TN after the initial cultures with the designated combinations of cytokines, GTS, GTF, and GTSF. As shown in Fig. 5 , the percentage of CD83 + CD86 + functional DCs, induced by G4TN after the initial cultures with GTF (Fig. 5b) , was significantly higher than those induced after the other two initial combinations (Fig. 5a and c) . These results suggest that FL can accelerate the differentiation of HPCs to pDCs, which are potentially ready to become APCs expressing surface costimulatory molecules.
We also estimated the functional properties of culturegenerated DCs by assessing their stimulating activity against proliferation of allogeneic T-lymphocytes. Representative data from three independent experiments are shown in Fig. 6 . As clearly shown, DCs generated by GTF+G4TN more potently induced allogeneic T-cell responses than those generated by GTS+G4TN or GTSF+G4TN. These results again illustrate that FL did advantageously induce the differentiation of HPCs to pDCs, which are ready to fully function as APCs in T-cellmediated immune responses.
Discussion
DCs are known as the professional APCs (6-8). Namely, they play an important role of capturing and processing antigen 
and presenting it to naïve helper T-cells to initiate the immune responses, including cytotoxic T lymphocyte (CTL) induction (5-7). Based on these findings, many doctors try to develop DC-based cancer immunotherapy (31).
Since G-CSF mobilizes monocytes as well as HPCs/HSCs in PB (34), many investigators used leukapheresis products to generate DCs for cancer immunotherapy (33,35). However, recent studies have suggested that monocytes mobilized by G-CSF have a T helper (Th)-2 type cytokine production profile (36) . In fact, G-CSF was reported to suppress the production of IL-12 and TNFα (37, 38) . Furthermore, another study suggested that G-CSF mobilizes DC2, not DC1, which stimulate T cell response into Th-2 type (36, 39) . Collectively, apheresis products obtained by G-CSF may not be useful as a cell source for DC-based cancer immunotherapy, because Th-1 type immune response is required for elimination of tumor cells. In this context, we have investigated if apheresis products mobilized by G-CSF could be used for cancer immunotherapy considering their cytokine production profiles and the immune responses elicited by DCs generated from monocytes obtained after G-CSF mobilization (40) . As a result, consistent with a previous report (41) , these generated DCs were phenotypically and functionally equivalent to DCs generated from control monocytes. In fact, we have demonstrated that peptide-pulsed DCs generated in this manner could elicit optimal cytotoxic T-cell responses in some patients in a clinical study for cancer immunotherapy on patients bearing CEA-expressing solid cancer (42) . On the other hand, we also previously demonstrated that a substantial number of CD34 + cells were mobilized in the peripheral blood and thus proposed the potential use of these G-CSF-mobilized CD34 + cells as a cell source for the expansion of pDCs in vitro (40) . In the present study, we tried to address this possibility and also assessed their further use in the more efficient production of mature DCs for future cancer immunotherapy.
The ex vivo expansion and differentiation of myeloid DCs from PB-derived CD34 + HPCs require a combination of various cytokines, as previously reported (24, 25, 43) . It is well documented that there are three types of cytokine-generated DCs, including two types of myeloid DCs, such as CD14 + blood monocyte-derived DCs and CD34 + HPC-derived DCs, and CD11c-negative lymphoid DCs (44) . Interestingly, CD34 + HPCs can give rise to any or all types of these DCs under the influence of particular cytokines in vitro. Among them, GM-CSF and IL-3 are the key cytokines to generate myeloid and lymphoid DCs, respectively (44) . TNFα, IL-4, transforming growth factor ß, IL-10, and vascular endothelial growth factor support or suppress the maturation/differentiation of these DCs (44) . On the other hand, it was reported that SCF and FL, which are known to be early-acting cytokines (32), could support pDC expansion (24,25). SCF stimulates DC formation from human BM-and CB-derived CD34 + cells in combination with GM-CSF and TNFα without affecting DC differentiation (31,45). FL also increases the production of DCs from BMderived CD34
+ cells in combination with GM-CSF+IL-4 +TNFα (46, 47) . This enhanced DC production is similar to the observed effects of SCF. However, as with SCF, FL does not affect the differentiation of DCs, but rather enhances the proliferation (46, 47) . From another point of view, FL differs somewhat from SCF when used singly in vivo; however, it can increase both myeloid and lymphoid DCs (48) . Preclinical human trials indicate a similar increase in circulating DCs, however, the precise mechanisms of action of these two cytokines remains unclear. In addition, FL has been reported to induce DC differentiation in vivo (46) . However, precisely how the FL acts on CD34 + HPCs and/or pDCs thus inducing them to generate mature DCs remains to be elucidated. It was therefore considered to be necessary to truly understand the basic mechanisms of actions of FL on these DC precursor cells, in order to clarify the role of FL in vivo and to develop more effective anti-cancer immunotherapy in the near future.
In this context, we herein focused on the precise effects of FL on the process of DC maturation of human PB-derived CD34 + HPCs. Our data clearly demonstrated that FL has more potent and specific actions on human DC development, compared to SCF, another early-acting cytokine. Of note was that FL, in combination with GM-CSF plus TPO, induced a dramatic effect on the ex vivo expansion of CFU-DCs (Fig. 2) (Figs. 3 and 4) . These pDCs could then mature into CD14 -
CD11c
+ CD1a + DCs in the presence of GM-CSF, IL-4, and TNFα. These mature DCs express co-stimulatory molecules, such as CD83 and CD86 (Fig. 5) . Importantly, these GTFgenerated mature DCs induce the most potent allogeneic T-cell responses in MLR in comparison to those of GTS and GTSF (Fig. 6 ). Both FL and SCF can expand pDCs as previously reported (24,25). However, our results indicate for the first time that in comparison to SCF, FL acts differently on CD34 + HPCs, where it induced the proliferation/differentiation of G-CSF-mobilized PB-derived CD34 + cells to pDCs in the presence of GM-CSF and TPO.
In conclusion, our present study clearly demonstrated that a combination of GTF could efficiently expand CFU-DCs and generate functional mature DCs in vitro. Therefore, it is possible to develop a more efficient DC-based cancer immunotherapy using this specific cytokine combination, GM-CSF+TPO+FL in vitro in the near future. FLT3 
